Register for our free email digests:
Division of Trillium Therapeutics Inc.
Latest From Thermo Fisher Scientific Inc.
US FDA Device-approval volumes were strong during the first half of 2017 for all review pathways. Medtronic and Siemens have so far captured the most 510(k) clearances, with Cook close behind. That and more from Medtech Insight's Approvals Tracker.
US FDA recently approved Oncomine Dx Target Test, the first multi-drug next-generation sequencing test made by Thermo Fisher Scientific. The test is a companion diagnostic for lung-cancer drugs made by Novartis and Pfizer, and the diagnostic company is looking to expand its partnership to other pharma companies.
The latest drug development news and US FDA highlights from our Performance Tracker.
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in May 2017.
- Large Molecule
- Therapeutic Areas
- Gynecological, Urological
- Transplantation Technologies Inc.
- North America
- Parent & Subsidiaries
- Trillium Therapeutics Inc.
- Senior Management
Niclas Stiernholm, PhD, CEO
Bob Uger, PhD, VP, R&D
Eric L Sievers, MD, CMO
- Contact Info
Phone: (416) 595-0627
96 Skyway Ave.
Toronto, M9W 4Y9
You must sign in to use this functionality
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.